Abstract: Provided herein are methods of treating a subject having hepatitis B viral (HBV) infection. More specifically, disclosed herein are methods of stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular agonists of STING to suppress HBV replication in hepatocytes. The methods are especially suitable for use in the treatment of chronic HBV infections. Also disclosed herein are methods of identifying compounds useful in the treatment of HBV infection.

Abstract: The present invention is directed toward novel compounds and novel methods of use of said compounds of the formula (I), useful as nucleocapsid assembly inhibitors for the treatment of viruses, especially but not exclusively, including pregenomic RNA encapsidation inhibitors of HBV for the treatment of Hepatitis B virus (HBV) infection and related conditions. including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, and R8 are defined herein.

Abstract: Provided herein are methods of treating a subject having hepatitis B viral (HBV) infection. More specifically, disclosed herein are methods of stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular agonists of STING to suppress HBV replication in hepatocytes. The methods are especially suitable for use in the treatment of chronic HBV infections. Also disclosed herein are methods of identifying compounds useful in the treatment of HBV infection.

Abstract: Level-shifter circuits and methods of using the same are provided. A level-shifter circuit includes a latch unit and a level-shifting unit. The latch unit is configured to generate a latch signal for storing a logic state of a first digital signal in a first power supply domain. The level-shifting unit is configured to shift a voltage of the latch signal to output a second digital signal in a second power supply domain. The latch unit and the level-shifting unit are powered by a power supply voltage in the second power supply domain.

Abstract: The present disclosure provides a cover sheet for a microarray reaction device. In one aspect, the present cover sheet or device ensures the reaction units/volumes are stable and/or consistent among assay samples and assay runs, allowing samples (e.g., reaction solutions) to be conveniently added and distributed uniformly.

Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

Abstract: A blade includes an airfoil, a stationary portion coupled to a radially inner end of the airfoil, and a leakage flow guide vane assembly coupled to the stationary portion. The leakage flow guide vane assembly includes a plurality of passages defined therein. The passages are oriented to induce a swirl velocity to a working fluid flowing through the passages.

Abstract: A bandgap reference circuit and method of using the same are provided. The bandgap reference circuit includes a startup component; an output component; and a bandgap core component coupled there-between. The bandgap core component includes a reference point having a voltage associated with an output signal of the output component. A controller is configured for controlling the bandgap core component and the output component to switch between a low power consumption mode and a normal operation mode based on the voltage at the reference point. When the bandgap core component and the output component operate in the normal operation mode, the bandgap reference circuit outputs a stable voltage and has a first power consumption. When the bandgap core component and the output component operate in the low power consumption mode, the bandgap reference circuit has a second power consumption less than the first power consumption.

Abstract: It discloses a compound of formula I that inhibits the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compound can be used for treating cancers, autoimmune diseases and inflammatory diseases.

Abstract: The present invention provides novel compounds of formula (I) and methods of use thereof. In certain embodiments, the compounds of the invention are useful as nucleocapsid assembly inhibitors. In other embodiments, the compounds of the invention are useful as pregenomic RNA encapsidation inhibitors of Hepatitis B virus (HBV). In yet other embodiments, the compounds of the invention are useful for the treatment of viral infection, including HBV and related viral infections.

Abstract: The present disclosure is directed to a method for scaling an airfoil for placement in a turbomachine. The method disclosed herein includes radially scaling a master airfoil to form a scaled airfoil. The method may also include tuning the scaled airfoil. For example, tuning the scaled airfoil may include axially scaling. The scaled airfoil generally has similar characteristics to the master airfoil.

Abstract: Various embodiments include a system having: at least one computing device configured to design a flow path in a steam turbine by performing actions including: for each component in a set of steam path components in the steam turbine: calculate an aspect ratio or a radius ratio for the component; design a shape of the component based upon the calculated aspect ratio or radius ratio; determine a seal type for the component based upon the calculated aspect ratio or radius ratio; and determine a size of a cavity adjacent the component based upon the calculated aspect ratio or radius ratio, the shape of the component and the seal type.

Abstract: A wireless telecommunication system is described comprising a shared base station able to divide resources between multiple network operators sharing the base station. The base station resources are divided into sets of resources reserved for each network operator respectively and resources shared by all network operators. The shared base station is configured to monitor the usage of its resources by each operator and to determine, for each scheduling round, an appropriate prioritization of communication bearers associated with the network operators.

Abstract: The present invention provides sulfamoylbenzamide derivatives, and pharmaceutical compositions thereof. In certain embodiments, the compounds and pharmaceutical compositions of the invention inhibit pregenomic RNA encapsidation. In other embodiments, the compounds and pharmaceutical compositions of the invention are useful for treating Hepatitis B virus (HBV) infection.

Abstract: A method for wiring differential signal lines and a PCB are disclosed. The wiring method includes: providing a rectangle-shaped glass fiber fabric formed of glass fibers which are woven and interlaced with each other and an adhesive filled therebetween; determining a wiring direction and obtaining a glass fiber bundle number of the glass fiber fabric in the wiring direction; equally dividing the glass fiber fabric into glass fiber units, and obtaining a width of each glass fiber unit according to a size of the glass fiber fabric in a direction perpendicular to the wiring direction and the number of the glass fiber units; determining a line distance and line widths of the differential signal lines; and according to the line distance and the line widths, forming the differential signal lines on a metal layer along the wiring direction to make the differential signal lines meet predetermined requirements.

Abstract: A cable is provided and includes a first conductor, a second conductor, and a PTC material layer. The PTC material layer is directly bonded to and electrically connects the first conductor and the second conductor.

Abstract: The present invention provides small molecule inhibitors of hepatitis B virus (HBV) covalently closed circular (ccc) DNA, which are useful as therapeutics in the management of chronic HBV. The compounds of the invention achieve epigenetic modification of the cccDNA, histone modification and histone deacetylase activity inhibition, thus modulating HBV cccDNA. The present invention further provides methods for modulating HBV cccDNA, for treating or preventing HBV in a subject, and for modulating cccDNA transcription of hepatitis B in a subject.

Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

Abstract: Provided herein are methods of treating a subject having hepatitis B viral (HBV) infection. More specifically, disclosed herein are methods of stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular agonists of STING to suppress HBV replication in hepatocytes. The methods are especially suitable for use in the treatment of chronic HBV infections. Also disclosed herein are methods of identifying compounds useful in the treatment of HBV infection.

Abstract: The present invention provides sulfamoylbenzamide derivatives, and pharmaceutical compositions thereof. In certain embodiments, the compounds and pharmaceutical compositions of the invention inhibit pregenomic RNA encapsidation. In other embodiments, the compounds and pharmaceutical compositions of the invention are useful for treating Hepatitis B virus (HBV) infection.